TY - JOUR

T1 - Extracts of Daedaleopsis Confragosa F-1368 Inhibit In Vitro and In Vivo the Proliferation of Human Cancer Cells

AU - Solovieva, O. I.

AU - Razumov, I. A.

AU - Teplyakova, T. V.

AU - Zavjalov, E. L.

N1 - The studies are supported by the budget project (No. FWNR-2022-0023) and implemented using the equipment of the Center for Genetic Resources of Laboratory Animals «SPF-vivarium» at the FRC Institute of Cytology and Genetics SB RAS, supported by the Ministry of Education and Science of Russia (RFMEFI62119X0023).

PY - 2024/6

Y1 - 2024/6

N2 - The aim of this study was to evaluate the effects of two variants of the Daedaleopsis confragosa fungus extract, F-1368 strain, differing in polysaccharide concentration, on five human cancer cell lines (U-87 MG, C-33 A, SK-Mel-28, MDA-MB-231, SW620) in vitro. Standard cytotoxicity assessment methods, including MTT-assay and clonogenic assay, were employed. Additionally, an experiment was conducted on laboratory SCID mice with heterotopic xenografts of human glioblastoma U-87 MG, where the test preparations were administered subcutaneously into the tumor area. Tumor sizes were measured using a caliper, and upon euthanasia, xenografts were histologically examined with hematoxylin-eosin staining under a light microscope. Results from MTT and clonogenic assays demonstrated that F-1368 extracts reduced the viability, mitochondrial function, and proliferative activity of tumor cells in vitro. However, a threefold increase in polysaccharide concentration in one of the extracts did not significantly enhance its cytotoxicity against tumor cells in vitro. Furthermore, one extract was tested on U-87 MG cell xenografts, revealing a reduction in tumor growth in SCID mice. The maximum tumor growth inhibition index for U-87 MG cells reached 50.7% at 21 days post-commencement of extract injections. These findings suggest that the D. confragosa F-1368 strain holds promise for investigating both in vitro and in vivo models of antitumor activity and identifying potential bioactive molecules or compounds.

AB - The aim of this study was to evaluate the effects of two variants of the Daedaleopsis confragosa fungus extract, F-1368 strain, differing in polysaccharide concentration, on five human cancer cell lines (U-87 MG, C-33 A, SK-Mel-28, MDA-MB-231, SW620) in vitro. Standard cytotoxicity assessment methods, including MTT-assay and clonogenic assay, were employed. Additionally, an experiment was conducted on laboratory SCID mice with heterotopic xenografts of human glioblastoma U-87 MG, where the test preparations were administered subcutaneously into the tumor area. Tumor sizes were measured using a caliper, and upon euthanasia, xenografts were histologically examined with hematoxylin-eosin staining under a light microscope. Results from MTT and clonogenic assays demonstrated that F-1368 extracts reduced the viability, mitochondrial function, and proliferative activity of tumor cells in vitro. However, a threefold increase in polysaccharide concentration in one of the extracts did not significantly enhance its cytotoxicity against tumor cells in vitro. Furthermore, one extract was tested on U-87 MG cell xenografts, revealing a reduction in tumor growth in SCID mice. The maximum tumor growth inhibition index for U-87 MG cells reached 50.7% at 21 days post-commencement of extract injections. These findings suggest that the D. confragosa F-1368 strain holds promise for investigating both in vitro and in vivo models of antitumor activity and identifying potential bioactive molecules or compounds.

KW - Daedaleopsis confragosa

KW - F-1368

KW - U-87 MG

KW - anticancer activity

KW - antitumor activity

KW - glioblastoma

KW - mycotherapy

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85197893009&origin=inward&txGid=606be8c7307728efe635ab72e146d714

UR - https://elibrary.ru/item.asp?id=67980401

UR - https://www.mendeley.com/catalogue/94ea53d6-c073-3489-9c9b-7722d2133be5/

U2 - 10.24412/2500-2295-2024-2-139-147

DO - 10.24412/2500-2295-2024-2-139-147

M3 - Article

VL - 11

SP - 139

EP - 147

JO - Opera Medica et Physiologica

JF - Opera Medica et Physiologica

SN - 2500-2287

IS - 2

M1 - 12

ER -